Pregled bibliografske jedinice broj: 1267182
Tumor selective Ru(III) Schiff bases complexes with strong in vitro activity toward cisplatin- resistant MDA-MB-231 breast cancer cells
Tumor selective Ru(III) Schiff bases complexes with strong in vitro activity toward cisplatin- resistant MDA-MB-231 breast cancer cells // Journal of biological inorganic chemistry, 28 (2023), 3; 263-284 doi:10.1007/s00775-023-01989-0 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1267182 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Tumor selective Ru(III) Schiff bases complexes
with strong in vitro activity toward cisplatin-
resistant MDA-MB-231 breast cancer cells
Autori
Pavlović, Marijana ; Kahrović, Emira ; Aranđelović, Sandra ; Radulović, Siniša ; Ilich, Predrag-Petar ; Grgurić-Šipka, Sanja ; Ljubijankić, Navzeta ; Žilić, Dijana ; Jurec, Jurica
Izvornik
Journal of biological inorganic chemistry (0949-8257) 28
(2023), 3;
263-284
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Apoptosis ; Breast cancer ; Cytoselectivity ; Ru(III) ; Schiff bases
Sažetak
Novel ruthenium(III) complexes of general formula Na[RuCl2(L1-3-N, O)2] where L(1-3) denote deprotonated Schiff bases (HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy, and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction of C1-C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron spectroscopy and fluorescence quenching. The cytotoxic activity of C1-C3 was investigated in a panel of four human cancer cell lines (K562, A549, EA.hy926, MDA-MB- 231) and one human non-tumor cell line (MRC-5). Complexes displayed an apparent cytoselective profile, with IC50 values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 µM. Cisplatin- resistant triple-negative breast cancer cells MDA- MB-231 displayed the highest sensitivity to complexes, with Ru(III) compound containing two chlorides and two deprotonated N-propyl-5-chloro- salicylidenimine (hereinafter C1) as the most potent (IC50 = 1.6 µM), and approximately ten times more active than cisplatin (IC50 = 21.9 µM). MDA-MB-231 cells treated for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation study by inductively coupled plasma mass spectrometry (ICP- MS) demonstrated markedly higher intracellular accumulation of C1 compared with cisplatin.
Izvorni jezik
Engleski
Znanstvena područja
Fizika, Kemija, Biologija
Poveznice na cjeloviti tekst rada:
doi journals.scholarsportal.info www.researchgate.net pubmed.ncbi.nlm.nih.govCitiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE